Chenkui Miao, Jianzhong Zhang, Kai Zhao, Chao Liang, Aiming Xu, Jundong Zhu, Yuhao Wang, Yibo Hua, Ye Tian, Shouyong Liu, Chao Zhang, Chao Qin, Zengjun Wang
Oncotarget 2017 Jun 27Recent studies have demonstrated that microRNA-148/152 family emerges as a attractive biomarker for predicting tumor prognosis and progression. However, outcomes of different studies are controversial. Eligible Literature were searched through online databases: PubMed, EMBASE and Web of Science. A total of 24 eligible studies were ultimately enrolled in this meta-analysis. Results indicated that overexpression of miR-148/152 family was significantly correlated with enhanced overall/cause-specific survival (OS/CSS) (HR=0.63, 95% CI: 0.54-0.74). Stratified analysis indicated that high miR-148a and miR-148b expression predicted favorable OS/CSS (HR=0.76; 95% CI: 0.69-0.90) and (HR=0.49; 95% CI: 0.39-0.61), while miR-152 developed no significant impact (HR=0.40, 95% CI: 0.12-1.29). MiR-148/152 family was distinctly associated with superior OS/CSS in Asian (HR=0.53, 95% CI: 0.44-0.64), but not in Caucasian (HR=0.96, 95% CI: 0.82-1.13). Futhermore, miR-148/152 family expression also predicted longer disease/relapse/progression-free survival (DFS/RFS/PFS) (HR=0.37, 95% CI: 0.16-0.88). A significantly favorable DFS/RFS/PFS was observed in Asian (HR=0.21, 95% CI: 0.06-0.81) than that in Caucasian (HR=0.76, 95% CI: 0.31-1.87). miR-148/152 family overexpression also predicted longer DFS/RFS/PFS in tissues (HR=0.11, 95% CI: 0.01-0.98), but not in plasma/serum (HR=0.67, 95% CI: 0.38-1.18). Our meta-analysis demonstrated that overexpression of miR-148/152 predicted enhanced OS/CSS and DFS/RFS/PFS of cancer patients. MiR-148a/b family may serve as a potential prognostic factor in multiple human malignancies.
Chenkui Miao, Jianzhong Zhang, Kai Zhao, Chao Liang, Aiming Xu, Jundong Zhu, Yuhao Wang, Yibo Hua, Ye Tian, Shouyong Liu, Chao Zhang, Chao Qin, Zengjun Wang. The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget. 2017 Jun 27;8(26):43344-43355
PMID: 28574848
View Full Text